Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 12, 2012, Pages 2189-2198

  Zanotti, Laura ^a   Bignotti, Eliana ^a   Calza, Stefano ^a   Bandiera, Elisabetta ^a   Ruggeri, Giuseppina ^b   Galli, Claudio ^c   Tognon, Germana ^a   Ragnoli, Monica ^a   Romani, Chiara ^a   Tassi, Renata A ^a   Caimi, Luigi ^b   Odicino, Franco E ^a   Sartori, Enrico ^a   Pecorelli, Sergio ^a   Ravaggi, Antonella ^a,d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b AO Spedali Civili ^*  (Italy)

^c ABBOTT DIAGNOSTICS   (Italy)

^d Spedali Civili   (Italy)

Author keywords

Biomarkers; CA125; Diagnosis; Endometrial cancer; Human epididymis protein 4 (HE4); Prognosis

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; CA-125 ANTIGEN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84872867358     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0757     Document Type: Article

References (34)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491-505.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111: 436-47.
4. Doubilet PM. Diagnosis of abnormal uterine bleeding with imaging. Menopause 2011;18:421-4.
5. Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Greggi S, Mancuso S. CA 15-3 as a tumor marker in gynecological malignancies. Gynecol Oncol 1988;30:265-73.
6. Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007;104:435-42.
7. Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer 2002;12:372-5.
8. Kanat-Pektas M, Yenicesu O, Gungor T, Bilge U. Predictive power of sexual hormones and tumor markers in endometrial cancer. Arch Gynecol Obstet 2010;281:709-15.
9. Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol 2007;62: 28-36.
10. Hacker NF. Uterine cancer. In: Berek JS, Hacker NF, editors. Practical serum cancer antigen CA125 gynecologic oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:397-442.
11. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004;58:24-38.
12. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991;45:350-7.
13. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768-73.
14. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9.
15. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
16. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110:196-201.
17. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100:1315-9.
18. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009;23:331-5.
19. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011;104: 1418-25.
20. Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer 2011;21:1185-90.
21. Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011;412:1447-53.
22. Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol 2006;125:921-7.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 1988;44:837-45.
24. Sonoda Y, Barakat RR. Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2006;20:363-77.
25. Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol 2010;202:73.e1-e5.
26. Cherchi PL, Dessole S, Ruiu GA, Ambrosini G, Farina M, Capobianco G, et al. The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20:315-7.
27. Hareyama H, Sakuragi N, Makinoda S, Fujimoto S. Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma. J Clin Pathol 1996;49:967-70.
28. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 2005;50:585-90.
29. Jhang H, Chuang L, Visintainer P, Ramaswamy G. CA 125 levels in the preoperative assessment of advanced-stage uterine cancer. Am J Obstet Gynecol 2003;188:1195-7.
30. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53.
31. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1): S105-43.
32. DiSaia PJ, Creasman WT, editors. Clinical gynecologic oncology. 7th ed. Philadelphia, PA: Mosby Elsevier, 2007:159-61.
33. Lundstrøm MS, Høgdall CK, Nielsen AL, Nyholm HC. Serum tetranectin and CA125 in endometrial adenocarcinoma. Anticancer Res 2000;20:3903-6.
34. Hoskins PJ, Le N, Correa R. CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer. Gynecol Oncol 2011;120:52-5.